Skip to main content
Premium Trial:

Request an Annual Quote

Sorenson Genomics to Merge Identigene, GeneTree Arms Into Single Unit

NEW YORK (GenomeWeb News) — Sorenson Genomics has merged into a single segment its Identigene arm, which specializes in forensic-DNA research for law enforcement, and its GeneTree arm, which focuses on DNA-based paternity testing, the company said today.
Sorenson said the new unit will do business under the Identigene brand name and will continue to operate from Identigene’s bases in Houston and Salt Lake City.
Sorenson bought Identigene in June for an undisclosed sum. Identigene and GeneTree, both founded in the mid-1990s, perform forensics casework for law enforcement and DNA paternity testing, and the newly formed division will continue to offer both services, Sorenson said.
The reorganization comes one month after Sorenson said it is expanding its lab facilities and is boosting its staff in the Salt Lake City region. Sorenson also said it is buying new sequencers and sample-prep tools in an effort to expand its capacities five-fold.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.